Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

Lantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.

In the study, PF-07307405 showed efficacy of more than 70% in preventing Lyme disease. The vaccine candidate was found to be well tolerated with no identified safety concerns, acc ...

Armed with $95m in funding and a former Pfizer drug discovery specialist, Khartis Therapeutics has emerged with the aim of bringing a new treatment for an autoimmune disease that ...

The FDA has granted accelerated approval to BMS' Zenbexus, along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma.

The HARMONi-6 trial included patients with locally advanced or metastatic squamous NSCLC, regardless of PD-L1 expression. Credit: Saiful52 / Shutterstock.com. Summit Therapeutics’ partner Akeso has ...

Eli Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.

Remepy has secured $36m in Series A funds to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline.

The manufacturing floor represents the primary source of life sciences compliance risks and data integrity failures.

The CRISPR therapy, SNIPR001, was administered to the patient who had developed E. Coli following a single-patient emergency IND.

Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the round, Infinimmune garnered the interest ...

Epicrispr and Vaderis have secured $90m and $152m, respectively, to take their rare disease drugs to pivotal clinical development.